目的 分析新癀片抗炎鎮(zhèn)痛作用機(jī)制,通過蛋白組學(xué)方法尋找其作用的蛋白靶點(diǎn)。方法 大鼠隨機(jī)分成對(duì)照組、模型組、吲哚美辛(2 mg/kg)組以及新癀片23.8、47.5、95.0 mg/kg組。給藥組均ig給藥10 mL/kg,對(duì)照組及模型組ig給予同體積去離子水。1次/d,連續(xù)3 d。于末次給藥后30 min,除對(duì)照組外,在大鼠右后足墊部sc 1%角叉菜膠0.05 mL/只致炎。在致炎前和致炎后1、2 h,記錄大鼠抬足潛伏期。剖殺大鼠取肝臟,肝組織蛋白經(jīng)提取、雙向電泳、染色和圖譜分析,確定差異表達(dá)蛋白,進(jìn)行蛋白質(zhì)質(zhì)譜分析。結(jié)果 與模型組比較,新癀片23.8、47.5、95 mg/kg組差異表達(dá)蛋白個(gè)數(shù)依次為67、71、94,其中上調(diào)個(gè)數(shù)為10、11、33,下調(diào)個(gè)數(shù)為57、60、61;新癀片95 mg/kg組與吲哚美辛(2 mg/kg)組比較,差異表達(dá)蛋白89個(gè),其中上調(diào)27個(gè),下調(diào)62個(gè)。共鑒定出11個(gè)差異蛋白質(zhì)。與模型組比較,新癀片組均可以抑制Shank3、ANXA5、TPI、PSMA2表達(dá),增強(qiáng)PAH、LZTS1表達(dá)。結(jié)論 新癀片可調(diào)節(jié)的蛋白明顯增多,能夠抑制多種相關(guān)炎癥因子和腫瘤因子,增強(qiáng)抗炎因子及抑癌因子的表達(dá),為新癀片“增效”作用機(jī)制提供重要理論依據(jù)。

Objective To analyse anti-inflammatory and analgesic mechanism of Xinhuang Tablets, and to explore drug targeting pathways in protein levels by proteomics technology. Methods SD rats were randomly divided into control group, model group, indomethacin 2 mg/kg group, and Xinhuang Tablets 23.8, 47.5, and 95.0 mg/kg groups. Rats in indomethacin group and Xinhuang Tablets groups were ig administered with the dose of 10 mL/kg, while rats in control group and model group were given the same volume of ionized water, once daily. All rats were treated for 3 d. Except the control group, 1% carrangeenan was sc given into the right footpad of rats 0.05 mL to induce inflammation 30 min after the last administration. Before inflammation and 1 and 2 h after inflammation, foot lift latency was recorded. The animals were sacrificed to obtain livers for proteomics research. The proteins from liver tissue were extracted, two-dimensional electrophoresis, stained, and pattern analysis. Differentially expressed proteins were established, and the identified proteins were determined by the mass spectrometry. Results Compared with the control group, the numbers of differential express proteins in Xinhuang Tablets 23.8, 47.5, and 95.0 mg/kg groups were 67, 71, and 94, respectively. And 10, 11, and 33 proteins in Xinhuang Tablets groups were up-regulated, while 57, 60, and 61 proteins were down-regulated. Compared with the indomethacin group, there were 89 differentially expressed proteins in Xinhuang Tablets groups, including 27 up-regulated proteins and 62 down-regulated proteins. Eleven differentially expressed proteins were identified. Compared with the indomethacin group, Xinhuang Tablets could inhibit the expression of Shank3, ANXA5, TPI, and PSMA2, and enhanced the expression of PAH and LZTS1. Conclusion Xinhuang Tablets can regulate more proteins, and inhibit the expression of inflammatory/tumor-associated factors, enhanced the expression of anti-inflammatory cytokines and tumor suppressor factor, which can provide theoretical basis for impoving efficiency of Xinhuang Tablets mechanism.